Robin Jones, MBBS, MRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK, discusses results from part A of the Phase II/III RINGSIDE (NCT04871282) investigating 3 doses of the gamma secretase inhibitor, AL102, in desmoid tumors. Phase II is open-label with safety as the primary endpoint. Phase III is a double-blind, placebo-controlled study with progression-free survival (PFS) as the primary endpoint. 30 patients with progressive desmoid tumors were enrolled into Phase II. There were no deaths or life-threatening treatment-related adverse events (TREAEs). The most common AEs were diarrhea, rash, nausea, fatigue and stomatitis. In terms of efficacy, early volume and RECIST responses were observed in all 3 dose arms at week 16. Prof. Jones also discusses further efficacy responses. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.